Angered by a controversial Allergan (AGN) patent maneuver, a handful of lawmakers introduced a bill that would prohibit tribal sovereign immunity from being used to block certain types of patent challenges.

The move comes six months after Allergan transferred six patents for its best-selling Restasis eye treatment to the St. Regis Mohawk tribe, which has sovereign immunity and has attempted to use its status to block patent challenges filed by several generic drug makers.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy